Furthermore, the failure of Fbxw7mut to accelerate extrauterine tumours caused by Trp53 loss or mutation supports the hypothesis that Fbxw7 mutation confers greater selective advantage in endometrial malignancy, though this is currently unproven. This evidence concerns the gene FBXW7 and neoplasm.